Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I’m good with this.
Got some drugs in good markets currently, just need to capitalize. Hopefully the new school year starting in August-ish will bring the CNS market back with it as more schools open up.
“Why has Elaine gone silent for over a year with no material events” Who TF is Elaine
“Why has the stock price gone down while nasrats
Share count gone up” Because he literally gets paid in shares. Even if the price skyrocketed, his share count would continue to increase.
“Why would the CFO quit before the big great news” None of us have any idea why Carter left. All speculation. Could be bad, could be that he just wanted to try something new.
“Why would they need a another CFO or the we’re about to merge” I doubt we’re on the verge of a merger but you never know.
“Why does the CRO have so many shares.” What TF is a CRO
Re read your post. It is absolutely in everyone’s (every shareholder) best interest that this company is purchased for the highest price per share possible.
From another response
“The more shares the CEO owns, the less the potential buyout "price" is”
Whose name is attached to the shares is completely irrelevant for a buyout. The outstanding count is what matters. If share ownership by someone is increasing due to dilution of the total count, then yes that statement would be correct.
If we get bought out for a decent price, why should I give a damn how many shares Nasrat has? Him accumulating shares still means he’d rather take shares than USD. All the bullshit still boils down to the simple fact that it is in Nasrat’s best interest, along with ours, to ultimately have the share price rise. That’s where the true windfall is.
How does diluting a stock, of which he is the largest holder by a massive margin, help him?
Yeah it’s so obvious. They are scumbags. Have front run me on both bid and ask many times.
Heard that before, cya tomorrow
I agree with this. There have been multiple events in the past that could’ve been PR’d out. Facility upgrades, API quotas, passing FDA inspections, etc. Other big board stocks have outside coverage that we don’t, analyst updates and such. Gotta play the ball where it lies.
First full Q of both Adderalls on the market, right?
Financials Friday, Con Call Monday 11:30AM EST.
I’ll take a stab at it. There are such things as frivolous lawsuits - I know this for a fact as a family member was accused of negligence by a patient at her place of employment. This was a baseless claim and easily disputed by the evidence. Didn’t stop her from being deposed and having to worry about it and deal with it for about 1.75-2 years before the other party finally settled a week before trial was supposed to start. Luckily, her lawyer fees were covered by her employer. Who would cover Elite’s legal fees in the event of a suit over generic opioids or any other baseless claim, even if the suit ultimately had no merit?
We ready for roughly 7M+ in revenues reported in the next 2-3 weeks or so???
I’ll go 7.5mil.
@AMA or anyone else who knows:
About how long does it take for the recorded version of the CC to pop up on Elite’s site? Couldn’t listen live today due to work meeting.
You heard right, congrats!!!!!
Elite Pharmaceuticals Announces Commercial Launch of Generic Adderall XR(R) with Marketing Partner Lannett Company
NORTHVALE, NJ / ACCESSWIRE / March 31, 2020 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP) a specialty pharmaceutical company developing niche generic products, announced today that marketing partner Lannett Company, Inc. ("Lannett"), has commenced product launch of Elite's generic version of Adderall XR®, an extended-release mixed salt of a single entity Amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate) with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg capsules. Adderall XR®, including generic versions, have an estimated IQVIA™ market value of approximately $1.3 billion for the twelve months ending January 2020. Adderall XR® is a once-daily central nervous system stimulant and is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
This generic Adderall XR® product is jointly owned by Elite and SunGen Pharma LLC ("SunGen") and is the second product launched from their collaboration. Elite will manufacture and package the generic product on a cost-plus basis. Lannett Company, Inc. will be the exclusive U.S. distributor for the product and will provide sales, marketing, and distribution.
Interesting. Not attacking, just would like to get more of your thoughts on potential acquisition. Anything else making you think that other than lack of filings?
I’m enjoying the 50+% gains today too, WHOOP!! Go ELTP!!!
Lol minuscule ELTP volume doesn’t mean jack. Good stuff.
Caught my eye as well. I think we are overdue for the approval according to the 10 month goal but didn’t someone also say Nasrat expected approval in Q2? If so, still got till end of next month.
That isn’t a good thing?
Nice. The fentanyl crackdown by China, assuming they actually do it, should be a big positive for the U.S. A tough problem to deal with but looks like he’s trying!
Now if only the FDA would quit throwing up roadblocks for our ADFs...
#eltpfacts #gtfowithfakenews
Cant wait to see the goalposts move again once Elite moves up into the tens and then hundreds of millions of dollars in revenues.
Not a bad idea but Nasrat has mentioned in the past about avoiding building up inventory of raw materials or something to that effect prior to receiving approvals. Basically, you can’t be sure when your ANDA will be approved and a small company like Elite doesn’t have the resources to risk ruining batches of time-sensitive materials if ANDA approvals don’t come at the expected times. Just my thoughts. I do think we are due for Adderall IR launch any day now.
“Since we now know why adderall has not yet been launched”
What has changed?
“Looks like the launch has been scrubbed.”
lol. k.
Agree. Same stance longs have taken in regards to the growing list of ANDA filings, approvals, and launches. Intrinsic value of the company is growing whether the stock reflects it or not.
$400M IR Adderall launch imminent.
$1.6B ER ANDA approval imminent.
Another ANDA filing imminent.
Parkinson’s P3 trial results imminent.
“You know it. I know it. Everybody knows it.”
Yes, this. Nothing to lose and everything to gain.
Ready for an approval maybe in the next few days??
Doug hasn’t sold shares, period, as evidenced by a lack of a Form 4. Does he intend to? Maybe. No action taken yet.
Any other claim about this so far is a lie. Thanks, hope I helped anyone that was confused.
Show proof.
Never did it before so how could they do it “again”?
Cue the “but what if Elite is selling shares and not filing with the SEC” argument... LOL. Remember that one?
Good thing humans aren’t mice.
Those making the claim should provide supporting evidence.
Lmao. Well played.
Figured I’d let them over deliver rather than underwhelm. :)
This is correct. Isradipine was always a smaller generic from the outset. If it turns out to be therapeutic for a new patient population, excellent. If not, fine too. Elite has zero to lose and $$ to gain.
Has zero impact on Adderall IR and the extended release CNS drug likely to be approved in the next 1-2 months.